1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
688C19F62F9FC27D4852571F5004B4D0C
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/white-paper-best-practices-in-quality-assurance-and-risk-based-approach-for-the-biopharmaceutical-industry?opendocument
18
19opendocument
2054.234.114.202
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RAS




Products & Services

White Paper: Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry

Whitepaper Image

ID: GBC-WP03


Pages/Slides: 7


Published: Pre-2013


Delivery Format: PDF


 

License Options:

close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.

Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS

Please click on
"Buy Now" to obtain the free study findings for "Assurance and Risk-Based Approach for the Biopharmaceutical Industry."

If you would like to purchase the full study this summary is based on click here.

Industries Profiled:
Pharmaceutical; Health Care; Medical Device


Companies Profiled:
Abbott Laboratories; Boehringer-Ingelheim; Johnson & Johnson; Novartis; Eli Lilly and Company